Lilly's addiction, abemaciclib, is part of the same new class of breast Cancer treatments as Pfizer Inc's recently approved drug, Ibrance, which generated $643 million in 2016. After skin cancer, breast cancer is the most common cancer in women in the United States, according to the U.S. Centers for Disease Control and Prevention. About 40,610 women will die from breast cancer in 2017, the American Cancer Society estimates. Abemaciclib, which was granted U.S. Food and Drug Administration breakthrough therapy status for breast cancer in 2015, is also being tested for use in lung cancer. In August, Lilly elected to continue the late-stage study, even though an interim data evaluation suggested the combination treatment was not delaying disease progression.
Eli Lilly (NYSE:LLY) announces that a Phase 3 clinical trial, MONARCH 2, assessing abemaciclib in patients with relapsed/refractory HR+/HER2- breast cancer met its primary endpoint. Breakthrough Therapy-tagged abemaciclib is a cell cycle inhibitor that is designed to block the growth of cancer cells by inhibiting the enzymes CDK4 and CDK6. Participants treated with abemaciclib and fulvestrant (AstraZeneca's Faslodex) showed a statistically significant improvement in progression-free survival (PFS) compared to those receiving placebo and fulvestrant. It expects to file an additional application for MONARCH 2 in Q3. Detailed results will be presented at an upcoming medical conference.
collected by :Lucy William
No comments:
Post a Comment